SCHEMBL16923754

SCHEMBL16923754

CNc1ccc(-c2c3nc(c(-c4ccccc4)c4ccc([nH]4)c(-c4ccccc4)c4nc(c(-c5ccccc5)c5[nH]c2CC5)C=C4)C=C3)cc1

nearest known ligand 0.46

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ TOP1 P11387 4/20 0.46
▸ CYCS P99999 4/20 0.45
▸ TERT O14746 4/20 0.44
▸ STAT3 P40763 1/20 0.43
▸ STAT1 P42224 1/20 0.43
▸ ABCG2 Q9UNQ0 1/20 0.42
▸ ENPP2 Q13822 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16552330 0.91 TOP1 (0.54) TOP1CYCSTERTSTAT3STAT1
SCHEMBL19326495 0.90 TOP1 (0.44) TOP1CYCSTERTSTAT3STAT1
SCHEMBL10002104 0.88 TOP1 (0.53) TOP1CYCSTERTSTAT3STAT1
SCHEMBL16923752 0.88 TOP1 (0.46) TOP1CYCSTERTSTAT3STAT1
SCHEMBL19902008 0.87 TERT (0.43) TOP1CYCSTERTSTAT3STAT1
SCHEMBL16920360 0.87 TOP1 (0.43) TOP1CYCSTERTSTAT3STAT1
SCHEMBL18887296 0.86 TOP1 (0.49) TOP1CYCSTERTSTAT3STAT1
SCHEMBL6394334 0.85 TERT (0.57) TOP1CYCSTERTABCG2ENPP2
SCHEMBL19888946 0.83 TOP1 (0.43) TOP1CYCSTERTSTAT3STAT1
SCHEMBL25704253 0.82 TOP1 (0.46) TOP1CYCSTERTSTAT3STAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170252441-A1 COMPOUND AND METHOD PCI BIOTECH AS (NO) 2017-09-07 — — US disclosed
US-20170143811-A1 METHOD OF TREATING MELANOMA PCI BIOTECH AS (NO) 2017-05-25 — — US disclosed
US-20160206725-A1 COMPOUND AND METHOD FOR VACCINATION AND IMMUNISATION PCI BIOTECH AS (NO) 2016-07-21 — — US disclosed
US-20150202293-A1 CONJUGATE OF A PHOTOSENSITISER AND CHITOSAN AND USES THEREOF PCI BIOTECH AS (NO) 2015-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150202293-A1 CONJUGATE OF A PHOTOSENSITISER AND CHITOSAN AND USES THEREOF TLR3, CD47, TLR9 TOP1 2741/4885CYCS 3103/4885TERT 2440/4885
US-20170252441-A1 COMPOUND AND METHOD CSF3R, IL2, IL5 TOP1 2013/4885CYCS 2836/4885TERT 3202/4885
US-20170143811-A1 METHOD OF TREATING MELANOMA CD47, HLA-DRB1, CD74 TOP1 4132/4885CYCS 3661/4885TERT 765/4885
US-20160206725-A1 COMPOUND AND METHOD FOR VACCINATION AND IMMUNISATION TLR9, TLR3, TLR1 TOP1 3662/4885CYCS 4582/4885TERT 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback